Clinical Trial Update: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating fairly brief androgen suppression combined with stereotactic radiotherapy for high-risk prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED